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Psoriasis (PsO) is a chronic relapsing/remitting autoimmune skin disease, associated 
with an increased risk of other autoimmune disorders. Psoriatic arthritis (PsA) is a chronic 
inflammatory arthritis occurring approximately in 30% of PsO patients. Sporadic cases of 
association between PsO and autoimmune thyroid disorders (AITDs) have been reported. 
However, two different recent studies did not find any association between them. In 
patients with PsO and PsA, an association with AITD has been shown by most of the 
studies in adults, but not in the juvenile form. In PsA women and men, thyroid autoim-
munity [positive antithyroid peroxidase (AbTPO) antibodies, hypoechoic thyroid pattern] 
and subclinical hypothyroidism were more prevalent than in the general population. An 
association has been shown also in patients with PsO, arthritis, and inflammatory bowel 
disease, who have more frequently AITD. A Th1 immune predominance has been shown 
in early PsO, and PsA, with high serum CXCL10 (Th1 prototype chemokine), overall in 
the presence of autoimmune thyroiditis. This Th1 immune predominance might be the 
immunopathogenetic base of the association of these disorders. A raised incidence of 
new cases of hypothyroidism, thyroid dysfunction, positive AbTPO, and appearance of 
a hypoechoic thyroid pattern in PsA patients, especially in women, has been shown 
recently, suggesting to evaluate AbTPO levels, thyroid function, and thyroid ultrasound, 
especially in PsA women. Thyroid function follow-up and suitable treatments should be 
performed regularly in PsA female patients at high risk (thyroid-stimulating hormone within 
the normal range but at the higher limit, positive AbTPO, hypoechoic, and small thyroid).
Keywords: psoriasis, psoriatic arthritis, autoimmune thyroiditis, hypothyroidism, CXCL10, AbTPO, anti-
thyroglobulin antibodies
inTRODUCTiOn
Psoriasis (PsO) (1) affects about 2–4% of the population (2); it is a chronic relapsing/remitting 
autoimmune skin disease (1) and presents with itchy red, scaly patches, papules, and plaques, with 
different severity, from localized patches to general body coverage. PsO is classified in five types: 
plaque, guttate, inverse, pustular, and erythrodermic (3). These lesions are usually evident on the skin 
Abbreviations: AITDs, autoimmune thyroid diseases; AT, autoimmune thyroiditis; AbTg, anti-thyroglobulin antibodies; 
AbTPO, antithyroid peroxidase antibodies; FT4, free thyroxine; IBD, inflammatory bowel disease; IFN, interferon; IL, inter-
leukin; JIA, juvenile idiopathic arthritis; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis; RF, rheumatoid factor; 
TD, thyroid dysfunction; TSH, thyroid-stimulating hormone.
TAbLe 1 | Prevalence of thyroid autoimmunity in psoriasis (PsO), or psoriatic arthritis (PsA) patients, versus controls, in the studies that have an internal control group.
Reference PsO patients (n) Autoimmune thyroid disorder  
(AiTD)% in PsO patients
Controls (n) AiTD% in controls P
Antonelli et al. (12) 80 with PsA 12/36 of F patients (33%);  
11/44 of M patients (25%)
112 patients with 
rheumatoid arthritis; 
400 control subjects
33/180 of F controls (18%);  
10/220 of M controls (5%)
0.0001
Bianchi et al. (15) 42 with PsA AbTg prevalence 5%;  
anti-microsome antibodies prevalence 14%
52 AbTg prevalence 3%;  
anti-microsome antibodies prevalence 0%
<0.05
Gul et al. (16) 105 6 patients had increased AbTPO (6%);  
8 patients had increased AbTg (8%);  
3 patients had both increased AbTPO  
and AbTg (3%)
96 with tinea pedis AbTPO levels were increased in  
6 subjects (6%), AbTg levels were  
increased in 11 subjects (11%)  
and both of them were increased  
in 6 subjects (6%)
NS
Vassilatou et al. (17) 114 (30 of them 
with PsA)
Prevalence of autoimmune  
thyroiditis (AT) 20.2%
286 Prevalence of AT 19.6% NS
Fallahi et al. (18) 97 with PsA 34% thyroid autoimmunity 97 15% thyroid autoimmunity 0.002
AbTg, anti-thyroglobulin antibodies; AbTPO, anti-thyroperoxidase antibodies; F, females; M, males; NS, not significant.
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of elbows and knees, and also on scalp, palms of hands, and soles 
of feet. Psoriatic nail dystrophy is usually present in fingernails 
and toenails and can be an isolated sign. A genetic predisposition 
is very important in the pathogenesis of PsO; however, environ-
mental factors can activate the disease (1).
The skin epidermal layer grows rapidly in PsO (4), determin-
ing an abnormal production and an excess of skin cells (5), 
that are replaced in 3–5  days in PsO (while commonly every 
28–30 days) (6). These events are probably induced by the pre-
mature keratinocytes maturation, induced by the inflammatory 
cascade in the dermis (7). The immune competent cells go from 
dermis to epidermis and release different inflammatory cytokines 
[interleukin (IL)-1β, interferon (IFN)-γ, tumor necrosis factor-α, 
chemokine (C-X-C motif) ligand (CXCL)10, IL-6, IL-22] (8). In 
PsO, DNA can stimulate the dendritic cells, to produce IFN-α. 
The secretion of such inflammatory cytokines leads to stimulate 
the proliferation of keratinocytes (8).
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis 
that has a variable clinical presentation and occurs approximately 
in 30% of PsO patients (7, 9, 10). PsA typically affects the joints of 
the fingers and toes, and it is characterized by a painful inflamma-
tion of the joints and surrounding connective tissue. This process 
results in a sausage-shaped swelling of the fingers and toes called 
dactylitis (9). PsA can also affect the hips, spine (spondylitis), 
knees, and sacroiliac joint (sacroiliitis), and any other joint (11). 
Dermatologic manifestations of PsO appear before the manifesta-
tions of arthritis in about 75% of patients (10).
Psoriasis is associated with an increased risk of other auto-
immune disorders like ulcerative colitis, Crohn’s disease, and 
autoimmune thyroiditis (AT) too (12).
Here, we review the scientific literature about PsO, PsA, and the 
possible association with autoimmune thyroid disorders (AITDs).
PsO, PsA, AnD AiTD
Few case reports initially reported an association of PsO and 
Hashimoto’s thyroiditis (13, 14) (Table  1). A first system-
atic study by Bianchi et  al. (15) evaluated thyroid volume 
and function and the prevalence of anti-microsome and 
anti-thyroglobulin antibodies (AbTg) in 42 patients with PsA, 
versus 52 normal subjects, as controls. The average thyroid 
volume, measured at ultrasounds, was increased in compari-
son to controls. Patients with PsA had a raised prevalence of 
anti-microsome antibodies; thyroid involvement was confined 
to patients with active disease. These results suggested a signifi-
cant thyroid involvement in PsA patients. However, the study 
was basically a retrospective study, and it did not specify the 
selection criteria of the patients (15).
A second study evaluated the prevalence of thyroid disorders 
in PsA patients, conducting a complete thyroid work-out in 80 
PsA patients, versus control subjects extracted (1:5) from the 
general population (matched by age and gender), and 112 patients 
with rheumatoid arthrtitis (RA) (with similar iodine intake). PsA 
women had significantly more frequently a hypoechoic thyroid 
pattern, antithyroid peroxidase antibodies (AbTPO), and sub-
clinical hypothyroidism than control women, with a frequency 
comparable to that in RA patients (hypoechoic thyroid 31, 16, and 
36%; positive AbTPO titer 28, 12, and 31%; subclinical hypothy-
roidism 25, 8, and 12%, respectively). PsA and RA men showed 
more frequently hypoechoic thyroid pattern and positive AbTPO 
than control subjects (hypoechoic thyroid 16, 10, and 3%; posi-
tive AbTPO titer 14, 5, and 2%, respectively). PsA patients with 
subclinical hypothyroidism had a longer disease duration (years; 
19 ± 15 versus 11 ± 8, p = 0.03) and polyarticular involvement 
(p ≤ 0.05) than euthyroid PsA patients. Therefore, a significantly 
higher prevalence of thyroid autoimmunity (positive AbTPO, 
hypoechoic thyroid pattern) in PsA men and women, and of 
subclinical hypothyroidism in PsA women, than in the general 
population were evidenced (12). Conversely, a subsequent study 
investigated the frequency of rheumatic diseases in 65 patients 
(56 F, 9 M), suffering from AITD; antinuclear antibody and 
rheumatoid factor levels were also measured. Various rheumatic 
disorders were detected in 40 (62%) of patients with AITD: the 
most frequent were fibromyalgia, osteoarthritis, keratocon-
junctivitis sicca, and xerostomia. Autoimmune diseases were 
detected in 10 patients with AITD, and among them also PsO 
and PsA (19). A further study (20) evaluated the frequency of 
AITD in 80 children with juvenile idiopathic arthritis (JIA) (27 
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oligoarticular, 26 polyarticular, 17 enthesitis-related, 6 systemic, 
and 4 PsA), versus 81 healthy control subjects, matched by age 
and gender. AITD were found in four patients in the JIA group 
(5%). No significant difference between the study and control 
groups was observed in the frequency of circulating antithyroid 
antibodies, or AT, suggesting that in JIA there is no association 
with AITD (20).
A further study evaluated thyroid autoimmunity in 105 
patients with PsO (without PsA), versus 96 sex- and age-
matching controls (with tinea pedis). The levels of free thyroxine 
(FT4) resulted significantly increased in the PsO group; however, 
AbTPO and AbTg levels were not significantly different between 
the two groups. The study showed that the serum FT4 levels 
can increase in psoriatic patients. However, thyroid-stimulating 
hormone (TSH), FT4, or FT3 were not reported. Furthermore, 
an increase of FT4 should be related to TSH decreased levels, 
however any correlation was reported (16).
The association between PsO and inflammatory bowel 
disease (IBD) has been previously reported, even if potential 
associated comorbidities are not clear. A study (21) examined 
comorbidities in 146 patients diagnosed with both PsO and 
IBD, in comparison with those diagnosed with PsO-only (146, 
matched by gender, ethnicity, and age). Patients with both PsO 
and IBD (versus PsO-only) had significantly higher rates of 
hepatitis (6.2 versus 0.7%), AT (6.8 versus 2.1%), and diabetes 
(26.77 versus 11.0%), and 60 (41.1%) were diagnosed with 
seronegative arthritis, suggesting that patients with both PsO 
and IBD have more frequently AITD and arthritis (21).
The prevalence of 12 autoimmune diseases was also evalu-
ated in 25,885 people extracted from the general population in 
Sardinia (22). A high prevalence was observed for RA, ulcerative 
colitis, Crohn’s disease, type 1 diabetes, systemic lupus erythe-
matosus, celiac disease, myasthenia gravis, systemic sclerosis, 
multiple sclerosis, Sjogren’s syndrome, PsO/PsA (939 cases), and 
AT (2,619 cases). The statistical analysis of the comorbidity of 
autoimmune diseases shows that the number of people with more 
than one autoimmune disease was significantly higher than the 
expected number, both in women and men (22).
Another study (17) evaluated prospectively 114 PsO patients 
with disease duration of 5–38  years, 30 of them with PsA, in 
comparison with 286 age- and body mass index-matched sub-
jects. No difference in the prevalence of AT between PsO patients 
and controls (20.2 versus 19.6%) was present. The prevalence of 
AT in male and female PsO patients was similar (9.6 and 10.5%, 
respectively) unlike the increased, as expected, prevalence in 
female versus male controls (14.7 versus 4.9%). Detected cases 
with hypothyroidism due to AT were similar in PsO patients and 
controls (7.9 and 7.0%, respectively). However, the number of 
patients with PsA was low (23) and not sufficient to a reliable 
evaluation of AITD in these last patients (17).
Conversely, a subsequent study evaluated prospectively the 
prevalence of other autoimmune disorders in outpatient clinic 
in 3,069 consecutive patients with diagnosed chronic AT, with 
respect to two age- and sex-matched control groups: (a) a control 
group of 1,023 subjects, extracted from a random sample of 
the general population without thyroid disorders and (b) 1,023 
patients with non-toxic multinodular goiter drawn by the same 
random sample of the general population, with similar iodine 
intake. The results of our study demonstrated a significant 
increase of the prevalence of PsA in AT patients (24).
A more recent study (18) aimed to assess the incidence of new 
cases of clinical and subclinical thyroid dysfunction (TD) in a 
broad group of PsA patients versus a control group, matched by 
age and gender with a similar iodine intake. PsA patients with 
TD were excluded first, and new cases of thyroid disorders were 
evaluated in 97 PsA patients and 97 matched controls (median 
follow-up of 74 months in PsA versus 92 in controls). A raised 
rate of new cases of hypothyroidism, TD, positive AbTPO, and 
appearance of a small hypoechoic thyroid pattern in PsA, espe-
cially in female gender, compared to controls has been evidenced. 
Risk factors in female gender for the development of TD were 
TSH within the normal range but at the higher limit, positive 
AbTPO, and small thyroid volume (18).
Interferon-γ and Th1 cytokines/chemokines are involved 
in the pathogenesis of PsO. Activated T  cells and HLA-DR 
keratinocytes have been shown in active plaques (25). It has 
been shown that CXCL10, the Th1 prototype chemokine, and its 
receptor (CXCR)3 are present in keratinocytes and in the dermal 
infiltrate derived from active psoriatic plaques and that effective 
treatment of active plaques decreased the expression of CXCL10. 
Elevated circulating CXCL10 has been shown in PsO patients 
(25–28). The cellular infiltrate in acute plaques is constituted by 
5–8% CD3(−)CD56(+) NK cells, as indicated by immunohisto-
chemical techniques, especially localized in the mid and papillary 
dermis. NK lymphocyte migration toward CXCL10 is involved in 
the pathogenesis of PsO (27).
CXCL10 is a determinant chemoattractant for neutrophils, 
and an elevated infiltration and microabscess formation by 
neutrophils is a characteristic PsO feature. Different papers have 
shown a critical pathogenic role of neutrophils in PsO, particu-
larly in the first phases, leading to hypothesize that blocking 
neutrophil function could have therapeutic effectiveness in this 
disease (23, 29, 30).
Also, in PsA patients, high levels of CXCL10 are observed in 
synovial fluid, and in circulation. Th1  cells immune predomi-
nance has been also shown at the beginning of the disease, with a 
subsequent later decline in long-lasting PsO or PsA, suggesting a 
shift from Th1 to Th2 immune response in long duration diseases 
(31–33).
Also, AITD are Th1 immune-mediated autoimmune disor-
ders in which Th1 lymphocytes, IFN-γ, and IFN-γ dependent 
chemokines (CXCL9, CXCL10, CXCL11) play an important role 
(34, 35).
Serum levels of CXCL10 (the Th1 prototype chemokine) 
and CCL2 (the Th2 prototype chemokine) were measured in 37 
patients with PsA without AT (PsA) and 28 with AT (PsA + AT), 
and in gender- and age-matched controls. The results of the 
study demonstrated higher circulating CXCL10 and CCL2 
in PsA patients than in control subjects. Furthermore, serum 
CXCL10 (but not CCL2) levels in PsA patients were significantly 
higher in the presence of AT (36). These data suggested that a 
Th1 immune predominace, both in PsA such as in AT, might 
be the immunopathogenetic base of the association of these 
diseases.
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COnCLUSiOn
Psoriasis is associated with an increased risk of other autoim-
mune disorders like ulcerative colitis, Crohn’s disease, and celiac 
disease (37). Sporadic cases of association of PsO and AITD have 
been reported. However, two different recent studies did not find 
any association between PsO and AITD.
Psoriatic arthritis is a chronic inflammatory arthritis that 
occurs approximately in 30% of PsO patients. In patients with PsO 
and PsA, an association with AITD has been shown by most of 
the studies in adults, but not in the juvenile form. In PsA women 
and men, thyroid autoimmunity (positive AbTPO antibodies, 
hypoechoic thyroid pattern) and subclinical hypothyroidism 
were more prevalent than in the general population. An associa-
tion has been shown also in patients with PsO, arthritis, and IBD 
who have more frequently AITD.
A Th1 immune predominance has been shown in early PsO, 
and PsA, such as in AT, with high circulating levels of the Th1 
prototype chemokine CXCL10 overall in the presence of the 
association with AT. These data suggest that this Th1 immune 
predominance might be the immunopathogenetic base of the 
association of these disorders.
A very recent longitudinal study in PsA patients has shown 
a raised incidence of new cases of hypothyroidism, TD, 
positive AbTPO, and appearance of a small and hypoechoic 
thyroid in PsA, especially in female gender, compared to 
controls. Risk factors in female gender for the development 
of TD are TSH within the normal range but at the higher 
limit, positive AbTPO, and small thyroid volume, suggesting 
to evaluate AbTPO levels, thyroid function, and thyroid ultra-
sound, especially in PsA women. Thyroid function follow-up 
and suitable treatments should be performed regularly in PsA 
female patients at high risk TSH within the normal range but 
at the higher limit, positive AbTPO, hypoechoic, and small 
thyroid.
However, studies in larger number of patients are required to 
evaluate if routine thyroid screening could be beneficial for PsO 
patients.
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